Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Brain

Showing results (31-40 of 139) with videos related to

Pageof 14
Sort By:
Cancer|April 8, 2011
Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient managementLaurence Champion, Etienne Brain, Anne-Laure Giraudet, et al.
The Lancet. Oncology|February 14, 2018
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer GroupHans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, et al.
Breast (Edinburgh, Scotland)|July 29, 2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)Pierre Fumoleau, Kevin M Koch, Etienne Brain, et al.
Journal of Translational Medicine|July 27, 2010
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityChrystelle Brignone, Maya Gutierrez, Fawzia Mefti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trialJean-Yves Pierga, François-Clément Bidard, Claire Mathiot, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
International Journal of Cancer|March 26, 2013
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressivenessFlorence Lerebours, Geraldine Cizeron-Clairac, Aurelie Susini, et al.
Breast (Edinburgh, Scotland)|May 31, 2022
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progressionHans Wildiers, Thomas Meyskens, Sandrine Marréaud, et al.
International Journal of Radiation Oncology, Biology, Physics|February 23, 2010
Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?Caroline Daveau, Denise Stevens, Etienne Brain, et al.
American Journal of Clinical Oncology|June 3, 2009
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancerCarole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, et al.
Pageof 14

Showing results (31-40 of 139) with videos related to

Sort By:
Pageof 14
Cancer|April 8, 2011
Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient managementLaurence Champion, Etienne Brain, Anne-Laure Giraudet, et al.
The Lancet. Oncology|February 14, 2018
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer GroupHans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, et al.
Breast (Edinburgh, Scotland)|July 29, 2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)Pierre Fumoleau, Kevin M Koch, Etienne Brain, et al.
Journal of Translational Medicine|July 27, 2010
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityChrystelle Brignone, Maya Gutierrez, Fawzia Mefti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trialJean-Yves Pierga, François-Clément Bidard, Claire Mathiot, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
International Journal of Cancer|March 26, 2013
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressivenessFlorence Lerebours, Geraldine Cizeron-Clairac, Aurelie Susini, et al.
Breast (Edinburgh, Scotland)|May 31, 2022
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progressionHans Wildiers, Thomas Meyskens, Sandrine Marréaud, et al.
International Journal of Radiation Oncology, Biology, Physics|February 23, 2010
Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?Caroline Daveau, Denise Stevens, Etienne Brain, et al.
American Journal of Clinical Oncology|June 3, 2009
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancerCarole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, et al.
Pageof 14